Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — Q1 2026 Earnings Presentation
15 slides from Kymera Therapeutics's earnings presentation, Apr 30, 2026
Slide 1: First Quarter 2026 Quarterly Results Call
First Quarter 2026 Quarterly Results Call April 30, 2026
Slide 2: Agenda
Agenda Introduction Justine Koenigsberg, Vice President, Investor Relations Key Highlights and Business Update Nello Mainolfi, PhD, Founder, President and Chief Executive Officer Clinical Update Jared Gollob, MD, Chief Medical Officer Financial Review Bruce Jacobs, CFA, MBA, Chief Financial Officer
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and express statements about our strategy, business
Slide 4: 2016-2026: A Decade of Discovery and Progress in Motion
2016-2026: A Decade of Discovery and Progress in Motion 2016-2020: PIONEERING A NEW MODALITY Establishing TPD into a reproducible innovation engine Unlocked highly validated, undrugged targets with unmatched capabilities 2021-2026: DEMONSTRATING EARLY PROOF OF CONCEPT Advanced six new, first-in-clas
Slide 5: Building a Best-In-Industry Oral Immunology Pipeline
Building a Best-In-Industry Oral Immunology Pipeline Potential Patient Upcoming IND-Enabling Phase 1 Phase 2 Phase 3 Indications Opp.1 Milestones Immunology - Wholly-Owned Oral Small Molecule Degraders AD, Asthma, Ph2b AD Data: KT-621 – AD COPD, EoE, By mid-2027 STAT6 CRSwNP, CSU, PN, >140M Ph2b Ast
Slide 6: 2026 Outlook: Key Catalysts Ahead
2026 Outlook: Key Catalysts Ahead • Complete enrollment in BROADEN2 Phase 2b AD KT-621 study in 2026; report data by mid-2027 First-in-Class Oral • Advance BREADTH Phase 2b asthma study; report STAT6 Degrader data in late-2027 KT-579 • Present new preclinical data at key medical meetings First-in-Cl
Slide 7: KT-621: Potential to Transform Type 2 Inflammatory Diseases
KT-621: Potential to Transform Type 2 Inflammatory Diseases KT-621 has the potential to be a novel oral medicine capable of delivering biologics-like efficacy and safety KT-621 PARADIGM SHIFT >90% Differentiated approach to address currently treated with an ✓ underlying disease biology injectable wo
Slide 8: Unlocking a New Market in Type 2 Inflammatory Disease
Unlocking a New Market in Type 2 Inflammatory Disease Innovation Drives Growth >140M • New products and mechanisms have historically Diagnosed patients with expanded the market by reaching more patients Type 2 diseases1 Reducing Patient Burden Could Unlock Access Significant • An oral therapy would,
Slide 9: IRF5: A New Treatment Paradigm for Complex Autoimmune Diseases
IRF5: A New Treatment Paradigm for Complex Autoimmune Diseases Complex diseases are driven by multiple IRF5 hyperactivation impacts multiple validated inflammatory pathways disease-defining pathways SLE, IBD, RA, others KT-579 IRF5 Type I Cytokines Autoantibodies IFNs (Myeloid/T Cells) (B cells) Typ
Slide 10: KT-579: Compelling Preclinical Profile
KT-579: Compelling Preclinical Profile Novel oral mechanism with biologics-like activity to block multiple validated disease-defining pathways Robust Degradation Full Inhibition of IRF5 Excellent Preclinical Activity Superior Exquisite Selectivity in Relevant Cell Types Regulated Cytokines to Target
Slide 11: KT-579: First IRF5 Agent to Enter Clinical Evaluation
KT-579: First IRF5 Agent to Enter Clinical Evaluation Phase 1 Trial: Double-blind, Placebo-controlled SAD and MAD in Healthy Volunteers • Safety & tolerability of Key Trial Aim Part A Primary escalating single and Single Ascending Dose multiple doses of KT-579 Key trial aim is to show that (SAD) KT-
Slide 12: KT-621: Late Breaking Presentation at AAD
KT-621: Late Breaking Presentation at AAD “Targeting the Type 2 inflammatory pathway through STAT6 degradation is an exciting mechanism. The early data showing impact on both biomarkers and clinical measures support further development and the potential of this novel oral drug to benefit a larger pr
Slide 13: KT-621 Development Plan Enables Efficient Path to Registration Across All Type 2 Diseases
KT-621 Development Plan Enables Efficient Path to Registration Across All Type 2 Diseases Ph3 Ph2b AD Dose Ph3: AD (Initial), Dose Ranging EoE, CSU, PN, BP Ongoing Data expected by mid-2027 Ph1 HV Ph1b AD SAD-MAD Single Arm, Open Label ✓ Complete ✓ Complete Ph3 Ph2b Asthma Dose Ph3: Asthma (Initial)
Slide 14: First Quarter 2026 Income Statement
First Quarter 2026 Income Statement Three Months Ended March 31, 2026 2025 Collaboration revenue $ 34,365 $ 22,100 Operating expenses: Research and development $ 98,162 $ 80,255 General and administrative 20,357 16,271 Total operating expenses 118,519 96,526 Loss from operations (84,154) (74,426) To
Slide 15: Thank You Q&A
Thank You Q&A To ask a question, raise your virtual hand